Explore Research Innovation at the David Geffen School of Medicine
UCLA’s expertise in immunology ranges far and wide. Current UCLA faculty have developed best-in-class T-cell therapies for fighting and beating cancer and for world-leading transplant programs; they have made groundbreaking discoveries unlocking the genetics and cell biology of immunity and are building mathematical models of human health. Here, now, we are harnessing the power of the immune system to cure disease.
Steven Bensinger, VMD, PhD Immunity, Inflammation, Infection, & Transplantation (I3T) Theme Chair
“Major clinical advances over the last 10 years have enriched basic understanding of the immune system to the point of translation, and there is the promise of great successes with antibody therapies and other forms of immunotherapy. The value of close interactions among researchers studying cancer, infectious diseases, autoimmunity, and transplant rejection is now readily apparent.”- Steven Bensinger, VMD, PhD
Good question, we are glad you asked. At UCLA, our researchers say that there may not be a disease known to humankind that does not involve one aspect of the immune system or another.
That is why a wide range of investigators from the David Geffen School of Medicine at UCLA have made the immune system the driver of their scientific investigations. They believe the future of medicine depends on it. In that future, as pertains to immunology related research at UCLA, there are four focus areas. Those areas are immunity, inflammation, infection, and transplantation - or I3T.
With a world-class hospital and top-ranked departments of mathematics, computer science, human genetics and biological science, UCLA is positioned to be a world leader in the digital age of medicine. A well-established culture of collaboration across disciplines provides a strong foundation. UCLA’s physicians and scientists, our clinics, hospitals, and laboratories are located on one central, compact, urban campus. The next innovative collaboration is a short walk away.